-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
August 2017
-
David R. Gandara, MD
David R. Gandara, MD, was honored as the lung cancer “Giant of Cancer Care” in the 2017 Giants of Cancer Care® recognition program by OncLive. Awardees are selected by their […]
-
Promise of Smoke-Free Future Falls Short
Editor’s Note: IASLC Lung Cancer News is pleased to publish this article as part of its continuing focus on the expansion of “combustible tobacco” (cigarettes) to include non-combustible products and […]
-
Roman V. Petrov, MD, PhD
Roman V. Petrov, MD, PhD, has been appointed Assistant Professor, Department of Surgical Oncology, Fox Chase Cancer Center; and Assistant Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine, […]
-
Gideon M. Blumenthal, MD
Gideon M. Blumenthal, MD was named Acting Deputy Director, Office of Hematology & Oncology Products, US Food and Drug Administration, Silver Spring, US. Prior to this appointment, Dr. Blumenthal was […]
-
Q&A with Alice Shaw, MD, PhD
Based on global ALEX, has crizotinib been relegated to the therapeutic scrapheap when it comes to patients with ALK rearrangements? Or does it retain some role? The global ALEX study, […]
-
Q&A with Benjamin Solomon, MBBS, PhD, FRACP
Please give us a global perspective on the results of global ALEX. Will alectinib definitively displace crizotinib or ceritinib as the first-line treatment for ALK-rearranged non-small cell lung cancer (NSCLC)? […]
-
Comments on the 8th Edition of the TNM Classification of Lung Cancer
By Fabrice Barlesi, MD, PhD, and Eric Vallières, MD, FRCSC An article by Cynthia Kryder and Ramón Rami-Porta in the IASLC Lung Cancer News recently highlighted the innovations of the […]
-
IASLC Workshop in Lung Cancer Clinical Research
By Luis E. Raez, MD The IASLC-Latin American Group (LATAM) successfully organized another “Workshop in Lung Cancer Clinical Research,” as it has done before in other countries like Chile and […]
-
Robert L. Comis, MD
Clinical Trial Leader and Patient Champion Passes Away at 71 Robert L. Comis, MD, passed away suddenly in his home on May 10, 2017. He was 71. A leader in […]
-
World No-Tobacco Day 2017: Women Against Lung Cancer in Europe’s European Union Event on Primary Prevention
By Gian Piero Bandelli, MD, Federica Ferraresi, WALCE Advocate, and Silvia Novello, MD, PhD On the occasion of World No Tobacco Day 2017, Women Against Lung Cancer in Europe (WALCE), […]